Chen et al. [29] have reported both BACE1 and NF-κB p65 levels significantly increased in the brains of AD patients, and that increased NF-κB levels upregulate BACE1 promoter activity and BACE1 transcription. The gene discussed is NFKB1; the disease is Alzheimer disease.